Oslo Pensjonsforsikring AS Takes $570,000 Position in Amgen Inc. $AMGN

Oslo Pensjonsforsikring AS acquired a new stake in Amgen Inc. (NASDAQ:AMGN) during the 1st quarter, Holdings Channel.com reports. The firm acquired 1,621 shares of the medical research company’s stock, valued at approximately $570,000.

Other hedge funds have also recently bought and sold shares of the company. Robeco Institutional Asset Management B.V. increased its stake in Amgen by 10.0% during the 4th quarter. Robeco Institutional Asset Management B.V. now owns 481,453 shares of the medical research company’s stock worth $157,584,000 after buying an additional 43,884 shares during the period. Curtis Advisory Group LLC purchased a new position in Amgen in the 4th quarter valued at approximately $1,669,000. Adell Harriman & Carpenter Inc. boosted its position in Amgen by 7.9% in the 4th quarter. Adell Harriman & Carpenter Inc. now owns 22,008 shares of the medical research company’s stock valued at $7,204,000 after buying an additional 1,609 shares during the period. Fideuram Intesa Sanpaolo Private Banking S.P.A. acquired a new position in shares of Amgen in the fourth quarter worth $22,441,000. Finally, Robinhood Asset Management LLC acquired a new position in shares of Amgen in the fourth quarter worth $17,526,000. Institutional investors and hedge funds own 76.50% of the company’s stock.

Insiders Place Their Bets

In other Amgen news, SVP Nancy A. Grygiel sold 1,237 shares of the firm’s stock in a transaction on Monday, May 4th. The stock was sold at an average price of $323.73, for a total value of $400,454.01. Following the sale, the senior vice president directly owned 7,009 shares in the company, valued at $2,269,023.57. This trade represents a 15.00% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. 0.85% of the stock is currently owned by corporate insiders.

Wall Street Analysts Forecast Growth

Several analysts have recently issued reports on AMGN shares. UBS Group increased their price objective on Amgen from $400.00 to $420.00 and gave the company a “buy” rating in a research note on Monday, July 13th. Mizuho lifted their target price on Amgen from $295.00 to $303.00 and gave the company a “neutral” rating in a report on Tuesday, June 16th. Daiwa Securities Group lowered their target price on Amgen from $410.00 to $390.00 and set an “outperform” rating for the company in a research note on Wednesday, May 13th. Cantor Fitzgerald restated a “neutral” rating and set a $350.00 price target on shares of Amgen in a report on Monday, July 6th. Finally, Argus reduced their price target on Amgen from $400.00 to $375.00 and set a “buy” rating on the stock in a research report on Wednesday, May 20th. Two analysts have rated the stock with a Strong Buy rating, eleven have given a Buy rating, fifteen have issued a Hold rating and two have issued a Sell rating to the company. According to data from MarketBeat, the company presently has an average rating of “Hold” and an average price target of $356.62.

Amgen Trading Up 0.6%

Shares of NASDAQ:AMGN opened at $366.24 on Wednesday. Amgen Inc. has a 52 week low of $269.77 and a 52 week high of $391.29. The company’s 50 day moving average is $348.98 and its two-hundred day moving average is $351.05. The company has a market cap of $197.66 billion, a PE ratio of 25.49, a P/E/G ratio of 3.68 and a beta of 0.41. The company has a current ratio of 1.26, a quick ratio of 1.01 and a debt-to-equity ratio of 5.65.

Amgen (NASDAQ:AMGN) last released its quarterly earnings data on Thursday, April 30th. The medical research company reported $5.15 earnings per share (EPS) for the quarter, topping the consensus estimate of $4.77 by $0.38. The business had revenue of $8.62 billion during the quarter, compared to analysts’ expectations of $8.58 billion. Amgen had a net margin of 20.96% and a return on equity of 137.41%. The company’s revenue for the quarter was up 5.8% on a year-over-year basis. During the same period in the previous year, the company earned $4.90 EPS. Amgen has set its FY 2026 guidance at 21.700-23.100 EPS. Equities analysts predict that Amgen Inc. will post 22.31 earnings per share for the current fiscal year.

About Amgen

Amgen Inc (NASDAQ: AMGN) is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen’s work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen’s commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.